

February 11, 2020

Listing Department
BSE LIMITED

P J Towers, Dalal Street, Fort,
Mumbai – 400 001

Code: 532 321

Listing Department

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai – 400 051

Code: CADILAHC

Re.: Press Release

Dear Sir/Madam,

Please find enclosed a copy of press release dated February 11, 2020 titled “Zydus receives final approval from the USFDA for Fluocinonide Cream USP, 0.1%.”

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors’ at large.

Thanking you,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**



DHAVAL N. SONI
COMPANY SECRETARY

Encl.: As above

Zydus receives final approval from the USFDA for Fluocinonide Cream USP, 0.1%.

Ahmedabad, 11 February, 2020

Zydus Cadila has received the final approval from the USFDA to market Fluocinonide Cream USP, (US RLD - Vanos Cream) 0.1%. The drug is used to treat a variety of skin conditions (e.g., psoriasis, eczema, dermatitis, allergies, rash) and will be manufactured at the group's Topical manufacturing facility at Ahmedabad.

The group now has 279 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
